Rallybio

Rallybio EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Rallybio (RLYB) as of Nov 6, 2026 is -45.07 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -88.82 % — a change of -49.25% (higher).

EBIT/Assets

-45.07 %

YoY

-49.25%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Rallybio is 2025 -45.07 % . Operating Income to Assets Ratio (EBIT/Assets) of Rallybio was 2024 -88.82 % . It decreases by -49.25% higher compared to the previous year.

The Rallybio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-81.65 USD
Jan 1, 2020
-17.84 USD
Jan 1, 2021
-25.06 USD
Jan 1, 2022
-37.62 USD
Jan 1, 2023
-68.27 USD
Jan 1, 2024
-88.82 USD
Jan 1, 2025
-45.07 USD
The Rallybio EBIT/Assets history
YEAREBIT/AssetsYoY
-45.07 %-49.25%
-88.82 %+30.11%
-68.27 %+81.46%
-37.62 %+50.15%
-25.06 %+40.47%
-17.84 %-78.15%
-81.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rallybio Stock analysis

What does Rallybio do? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rallybio stock

Operating Income to Assets Ratio (EBIT/Assets) of Rallybio is -45.07 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Rallybio changed from -88.82 % to -45.07 %, representing a -49.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Rallybio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Rallybio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Rallybio

All Key Metrics — Rallybio